Ivacaftor was associated with improved ppFEV1 across all age groups, with the magnitude of improvement roughly 50% of that observed in clinical trials. The results support the need to account for modulator initiation bias and the use of within-subject analysis in future CFTR (cystic fibrosis transmembrane conductance regulator) modulator effectiveness studies, but caution is advised in younger individuals because of developmental changes that may affect pre- and post-treatment comparability.
Lung Sask in collaboration with RESPTREC® offers the Professional Education Portal as a method for respiratory educators and health care providers to enhance their professional learning with continuing education opportunities.
Over 6000+ more articles available in the Professional Education Portal.
Read articles and watch video presentations on the most recent research, position papers and guidelines. Track your CE time with the provided logbook.